经动脉化疗栓塞(TACE)联合经动脉灌注化疗(HAIC)对比单纯TACE治疗不可切除肝癌的疗效及安全性
Efficacy and Safety of Transcatheter Arterial Chemoembolization (TACE) Combined with Hepatic Arterial Infusion Chemotherapy (HAIC) Compared with TACE Alone for Unresectable Hepatocellular Carcinoma
DOI: 10.12677/ACM.2023.1351141, PDF,   
作者: 夏银锋*, 陈 红, 涂 兵#：重庆医科大学附属第二医院肝胆外科，重庆
关键词: TACE；HAIC；HCC；TACE； HAIC； HCC
摘要: 目的：比较TACE联合HAIC与单纯TACE方案治疗不可切除肝细胞癌的疗效及安全性。方法：该项研究为单中心回顾性研究，选取了2020年8月至2021年8月在重庆医科大学附属第二医院接受了TACE + HAIC或单纯TACE治疗的HCC患者共156人。分为TACE + HAIC方案组80人，单纯TACE方案组76人。结果：两组均无患者达到CR，TACE + HAIC组明显高于TACE组的客观缓解率(ORR) (46.3% vs 25.0%, p = 0.006)。而两组患者的DCR无明显差异(TACE + HIAC: 92.6% vs TACE: 85.5%, p = 0.162)。对两组的ORR与DCR之间进行了单因素logistic回归，结果显示ORR (OR: 0.387, 95%CI: 0.196~0.765, p = 0.006)，DCR (OR: 0.479, 95%CI: 0.168~1.368, p = 0.169)。以及多因素logistic回归分析显示ORR (OR: 0.291, 95%CI: 0.126~0.674, p = 0.004)，DCR (OR: 0.550, 95%CI: 0.161~1.876, p = 0.339)。结论：TACE + HAIC治疗晚期不可切除肝癌的疗效明显优于单纯TACE治疗。
文章引用：夏银锋, 陈红, 涂兵. 经动脉化疗栓塞(TACE)联合经动脉灌注化疗(HAIC)对比单纯TACE治疗不可切除肝癌的疗效及安全性[J]. 临床医学进展, 2023, 13(5): 8156-8162. https://doi.org/10.12677/ACM.2023.1351141

参考文献

[1] Li, M., et al. (2021) Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Ad-vanced Hepatocellular Carcinoma with Portal Vein Invasion. Frontiers in Oncology, 11, Article ID: 562135. [Google Scholar] [CrossRef] [PubMed]
[2] 中国抗癌协会肝癌专业委员会. 肝动脉灌注化疗治疗肝细胞癌中国专家共识(2021版) [J]. 中华消化外科杂志, 2021, 20(7): 754-759.
[3] Marrero, J.A., et al. (2018) Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 68, 723-750. [Google Scholar] [CrossRef] [PubMed]
[4] Heimbach, J.K., et al. (2018) AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology, 67, 358-380. [Google Scholar] [CrossRef] [PubMed]
[5] Song, D.S., et al. (2015) A Comparative Study between Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocel-lular Carcinoma with Portal Vein Tumor Thrombosis. Journal of Gastroenterology, 50, 445-454. [Google Scholar] [CrossRef] [PubMed]
[6] Kudo, M., et al. (2014) JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer, 3, 458-468. [Google Scholar] [CrossRef] [PubMed]
[7] Chen, C.T., et al. (2021) Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences, 22, Article No. 12880. [Google Scholar] [CrossRef] [PubMed]
[8] Choi, J.H., et al. (2018) Randomized, Prospective, Comparative Study on the Effects and Safety of Sorafenib vs. Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocel-lular Carcinoma with Portal Vein Tumor Thrombosis. Cancer Chemotherapy and Pharmacology, 82, 469-478. [Google Scholar] [CrossRef] [PubMed]
[9] Hatano, E., et al. (2018) Significance of Hepatic Resection and Adjuvant Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in the First Branch of Portal Vein and the Main Portal Trunk: A Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Journal of Hepato-Biliary-Pancreatic Sciences, 25, 395-402. [Google Scholar] [CrossRef] [PubMed]
[10] Jiang, Y.Q., He, Y.C., Liu, S. and Tao, Y.G. (2017) Chromatin Remodeling Factor Lymphoid-Specific Helicase Inhibits Ferroptosis through Lipid Metabolic Genes in Lung Cancer Progression. Chinese Journal of Cancer, 36, Article No. 82. [Google Scholar] [CrossRef] [PubMed]
[11] Niizeki, T., et al. (2021) Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carci-noma with Macrovascular Invasion. Cancers (Basel), 13, Article No. 4450. [Google Scholar] [CrossRef] [PubMed]
[12] Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC), Goyang, Korea (2019) 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 20, 1042-1113. [Google Scholar] [CrossRef] [PubMed]
[13] Kudo, M., Sakurai, T. and Nishida, N. (2015) General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan. Digestive Diseases, 33, 765-770. [Google Scholar] [CrossRef] [PubMed]
[14] Omata, M., et al. (2017) Asia-Pacific Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma: A 2017 Update. Hepatology International, 11, 317-370. [Google Scholar] [CrossRef] [PubMed]
[15] Abdelmaksoud, A.H.K., et al. (2021) Hepatic Arterial Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: A Case-Control Study. Clinical Radiology, 76, 709.e1-709.e6. [Google Scholar] [CrossRef] [PubMed]
[16] He, M.K., et al. (2017) Hepatic Artery Infusion Chemotherapy Using mFOLFOX versus Transarterial Chemoembolization for Massive Unresectable Hepatocellular Carcinoma: A Pro-spective Non-Randomized Study. Chinese Journal of Cancer, 36, Article No. 83. [Google Scholar] [CrossRef] [PubMed]
[17] Sung, P.S., et al. (2019) Reduction of Intrahepatic Tumour by Hepatic Arterial Infusion Chemotherapy Prolongs Survival in Hepatocellular Carcinoma. Anticancer Research, 39, 3909-3916. [Google Scholar] [CrossRef] [PubMed]
[18] Liu, B.J., et al. (2021) Combination Therapy of Che-moembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. BioMed Research In-ternational, 2021, Article ID: 6670367. [Google Scholar] [CrossRef] [PubMed]

为你推荐